Ozempic Alternatives: Every Option Ranked for 2026
Ozempic costs $998/month without insurance and is only FDA-approved for diabetes — not weight loss. Here are 7 alternatives ranked by cost, efficacy, and availability for 2026.
Why Look for Ozempic Alternatives?
At $998/month without insurance, Ozempic is one of the most expensive GLP-1 options. It is FDA-approved only for type 2 diabetes (not weight loss), supply shortages have been ongoing, and 40-70% of users experience gastrointestinal side effects. Whether you need a lower cost, a different mechanism, or simply an FDA-approved weight loss indication, there are now better options available.
Quick Answer
The best Ozempic alternative for most people is Wegovy ($249/mo via telehealth) — same semaglutide molecule, FDA-approved for weight loss, widely available. For the cheapest FDA-approved option, Foundayo at $149/mo is a daily pill with no fasting requirement. For maximum weight loss, Mounjaro/Zepbound (tirzepatide) delivers 15-22% body weight loss with its dual-action mechanism.
Why Are People Switching Away from Ozempic?
People switch from Ozempic primarily because of its $998/month retail cost, lack of FDA weight loss approval, ongoing supply issues, and the availability of newer alternatives with better pricing or efficacy.
Ozempic (semaglutide 0.5mg-2.0mg) was designed for type 2 diabetes, not weight loss. While doctors frequently prescribe it off-label for obesity, this creates insurance complications — most plans will not cover Ozempic for weight management. Meanwhile, the GLP-1 market has evolved rapidly:
- Cost: Ozempic retails at $998/month. Alternatives like Foundayo ($149/mo) and Wegovy subscriptions ($249/mo) are dramatically cheaper.
- Indication: Wegovy and Zepbound are FDA-approved for weight loss, making insurance coverage more likely.
- Efficacy: Tirzepatide (Mounjaro/Zepbound) produces 15-22% weight loss vs. Ozempic's 12-15%.
- Convenience: Foundayo and Oral Wegovy eliminate injections entirely.
- Supply: Ozempic has faced recurring shortages. Newer alternatives have more reliable supply chains.
7 Best Ozempic Alternatives in 2026
The best Ozempic alternatives range from $99/month (compounded) to $1,060/month (Zepbound retail), with weight loss ranging from 5% to 22% of body weight depending on the medication.
Wegovy (Semaglutide)
Same ingredient as Ozempic, FDA-approved for weight loss
Wegovy uses the same active ingredient as Ozempic (semaglutide) but at a higher dose (2.4mg vs 2.0mg) and is specifically FDA-approved for chronic weight management. Many telehealth providers now offer Wegovy subscriptions starting at $249/month, significantly below the $1,349 retail price. If your goal is weight loss rather than diabetes management, Wegovy is the most direct Ozempic alternative.
Advantages
- Same proven semaglutide molecule
- FDA-approved specifically for weight loss
- Widely available through telehealth at $249/mo
- Weekly injection (same convenience as Ozempic)
Drawbacks
- Retail price without insurance is $1,349/mo
- Similar GI side effects as Ozempic
- Requires ongoing use to maintain weight loss
Foundayo (Orforglipron)
New oral pill, no fasting required, FDA-approved April 2026
Foundayo (orforglipron) is Eli Lilly's groundbreaking oral GLP-1 pill that received FDA approval on April 1, 2026. Unlike oral semaglutide, Foundayo is a non-peptide small molecule that does not require fasting — you can take it with or without food. At $149/month, it is the most affordable FDA-approved GLP-1 option and eliminates the need for injections entirely.
Advantages
- Oral pill — no injections needed
- No fasting requirement (take with or without food)
- Lowest cost FDA-approved GLP-1 at $149/mo
- Non-peptide molecule (easier to manufacture)
Drawbacks
- Brand new (approved April 2026) — limited long-term data
- Slightly lower weight loss than injectable tirzepatide
- Daily dosing required
Mounjaro (Tirzepatide)
Dual-action GIP/GLP-1, highest weight loss in class
Mounjaro is FDA-approved for type 2 diabetes and works through a dual GIP/GLP-1 mechanism that produces the highest weight loss in the class — up to 22% body weight in clinical trials. While technically prescribed off-label for weight loss (its sister drug Zepbound holds the obesity indication), many providers prescribe Mounjaro for weight management. It is more expensive than semaglutide options but may be worth it for patients who need maximum efficacy.
Advantages
- Highest weight loss in class (15-22%)
- Dual GIP/GLP-1 mechanism
- Weekly injection
- Strong clinical trial data (SURMOUNT trials)
Drawbacks
- Expensive without insurance ($1,023/mo retail)
- Technically off-label for weight loss
- May cause more GI side effects during titration
Zepbound (Tirzepatide)
Same as Mounjaro, FDA-approved for obesity
Zepbound is the exact same molecule as Mounjaro (tirzepatide) but specifically FDA-approved for chronic weight management in adults with obesity or overweight with at least one comorbidity. If your insurance covers obesity medications but not diabetes drugs off-label, Zepbound may be the better path to tirzepatide. Eli Lilly also offers a savings program bringing costs as low as $550/month.
Advantages
- FDA-approved specifically for obesity
- Same powerful dual-action molecule as Mounjaro
- Insurance coverage improving in 2026
- Lilly savings program available
Drawbacks
- High retail cost ($1,060/mo without savings)
- Periodic supply constraints
- Same GI side effect profile as Mounjaro
Compounded Semaglutide
Cheapest option but carries FDA risks
Compounded semaglutide is the most affordable way to access a GLP-1 medication, with prices ranging from $99 to $299 per month through telehealth providers. However, the FDA declared the semaglutide shortage over in early 2025, removing the legal basis for many compounding pharmacies. The FDA has issued warning letters to over 50 compounders for contamination, incorrect dosing, and use of unapproved salt forms. Proceed with caution.
Advantages
- Most affordable GLP-1 option ($99-$299/mo)
- Widely available through telehealth
- No insurance required
Drawbacks
- Not FDA-approved
- FDA has issued 50+ warning letters to compounders
- Semaglutide shortage officially over (legal basis removed)
- Variable quality — contamination and dosing risks
Oral Wegovy (Semaglutide Tablets)
Pill form of Wegovy, requires fasting
Oral Wegovy launched in January 2026 as the first FDA-approved oral semaglutide for weight loss. The starting dose costs just $149/month, making it an attractive entry point. However, the maintenance dose (50mg) needed for full weight loss efficacy costs $500-$800/month. Unlike Foundayo, oral Wegovy must be taken on an empty stomach with only a small sip of water, then you must wait 30 minutes before eating.
Advantages
- No injections needed
- FDA-approved for weight loss
- Low entry price at $149/mo (starting dose)
- Same proven semaglutide molecule
Drawbacks
- Must take on empty stomach (30-min fasting window)
- Maintenance dose is $500-$800/mo
- Only ~1% bioavailability (variable absorption)
- Daily dosing required
Rybelsus (Oral Semaglutide)
Oral semaglutide for diabetes, off-label for weight loss
Rybelsus has been available since 2019 as an oral semaglutide for type 2 diabetes. Some providers prescribe it off-label for weight loss, but at a maximum dose of 14mg (compared to Oral Wegovy's 50mg), weight loss results are more modest — typically 5-8% body weight. It is best suited for patients with type 2 diabetes who also want moderate weight loss, rather than as a primary weight loss medication.
Advantages
- Oral pill — no injections
- Nearly 7 years of real-world safety data
- Good option for patients with type 2 diabetes
- Insurance commonly covers it for diabetes
Drawbacks
- Off-label for weight loss
- Lower dose means modest weight loss (5-8%)
- Same fasting requirement as Oral Wegovy
- Expensive without diabetes insurance coverage
Side-by-Side Comparison Table
| Drug | Type | Avg Weight Loss | Monthly Cost | Oral/Injectable | FDA Approved |
|---|---|---|---|---|---|
| Ozempic(current) | GLP-1 | 12-15% | $998/mo | Injectable | Diabetes only |
| Wegovy | GLP-1 | 15-17% | $249/mo* | Injectable | Weight loss |
| Foundayo | GLP-1 | 14-15% | $149/mo | Oral | Weight loss |
| Mounjaro | GIP/GLP-1 | 15-22% | $550-$1,023/mo | Injectable | Diabetes |
| Zepbound | GIP/GLP-1 | 15-22% | $550-$1,060/mo | Injectable | Weight loss |
| Compounded Semaglutide | GLP-1 | 12-15% | $99-$299/mo | Injectable | No |
| Oral Wegovy | GLP-1 | 15-17% | $149-$800/mo | Oral | Weight loss |
| Rybelsus | GLP-1 | 5-8% | $900-$1,000/mo | Oral | Diabetes only |
*Wegovy $249/mo reflects telehealth subscription pricing. Retail price is $1,349/mo without insurance. Compounded semaglutide is not FDA-approved. All pricing verified April 2026.
How to Choose the Right Ozempic Alternative
Choose based on three factors: your budget, whether you prefer pills or injections, and how much weight you need to lose.
On a Budget
Foundayo ($149/mo) is the cheapest FDA-approved option. Compounded semaglutide ($99-$299/mo) is cheaper but carries FDA safety risks. Wegovy subscriptions ($249/mo) balance affordability with a proven brand.
Hate Needles
Foundayo is the best oral option with no fasting required. Oral Wegovy is another pill option but requires 30 minutes fasting each morning. Rybelsus works for diabetic patients who want a pill.
Maximum Results
Mounjaro or Zepbound (tirzepatide) produce the highest weight loss at 15-22% — significantly more than semaglutide options. The dual GIP/GLP-1 mechanism is more effective for most patients.
Not sure which alternative is right for you?
Take our 2-minute quiz and get a personalized recommendation based on your budget, preferences, and health goals.
Take the GLP-1 Match QuizFrequently Asked Questions
What is the cheapest alternative to Ozempic in 2026?
The cheapest FDA-approved alternative is Foundayo (orforglipron) at $149/month — an oral pill that received FDA approval in April 2026. Compounded semaglutide is cheaper ($99-$299/month) but is not FDA-approved and carries contamination risks. Oral Wegovy starts at $149/month for the lowest dose, but the maintenance dose costs $500-$800/month.
Is there a pill version of Ozempic for weight loss?
Yes, two options exist. Oral Wegovy (semaglutide tablets) launched in January 2026 and is FDA-approved for weight loss, starting at $149/month. Foundayo (orforglipron), approved April 2026, is a different GLP-1 pill at $149/month that does not require fasting. Rybelsus is an oral semaglutide for diabetes but is only prescribed off-label for weight loss at a lower, less effective dose.
What works better than Ozempic for weight loss?
Tirzepatide (sold as Mounjaro for diabetes and Zepbound for obesity) produces 15-22% body weight loss in clinical trials, compared to Ozempic's 12-15%. This dual GIP/GLP-1 mechanism targets two hormones instead of one. Wegovy (same semaglutide molecule at a higher 2.4mg dose) also outperforms Ozempic's standard dosing.
Will Medicare cover Ozempic alternatives in 2026?
Yes. Starting July 1, 2026, the Medicare GLP-1 Bridge Program will cover Wegovy and Zepbound at $50/month for eligible Part D enrollees. Full Medicare Part D coverage begins in January 2027 under the BALANCE Model. This makes FDA-approved alternatives significantly more affordable for Medicare patients.
Can I switch from Ozempic to an alternative without restarting?
Switching between semaglutide products (Ozempic to Wegovy or Oral Wegovy) is typically straightforward since it is the same molecule, though your doctor may adjust dosing. Switching to tirzepatide (Mounjaro/Zepbound) or orforglipron (Foundayo) usually requires a new titration period starting at the lowest dose. Always consult your prescriber before switching — do not change medications on your own.